https://www.selleckchem.com/pr....oducts/Enzastaurin.h
6% to 60.7%. The prevalence of cirrhosis remained similar (5.8% in 2012 and 5.6% in 2016, p=0.69) while hepatocellular carcinoma decreased from 6.3% to 4.5% (p0.01). The prevalence of non-liver comorbidities increased (40.9% to 52.0% for cancer (p0.01), 12.1% to 17.7% for osteoporosis (p0.01), and 10.7% to 15.0% for renal impairment (p0.01). Healthcare resource utilization and costs also increased, with a 119.3% increase in the median total healthcare costs from ¥229,143 in 2012 to ¥502,467 in 2016 (p0.01). The C
Like
Comment
Share
